Blood disorders
Lymphoma in Hefei
合肥 淋巴瘤
4 hospitals in Hefei
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Hefei may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 16 papers ledNo open trial led
- 13 papers led
- 9 papers ledNo open trial led
- 0 papers ledNo open trial led
Lymphoma in every city Hefei on the disease page, with the national map
open trials on lymphoma with a hospital in Hefei
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Hefei as lead sponsor or study site. 3 of them are led by a hospital in Hefei. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingAnti CD19 Gene Therapy for B-cell Lymphoma
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07211048
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06717347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen
- RecruitingNewly-diagnosed Pediatric T-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06855810
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan
- RecruitingIntravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT06961669
Age 3 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingDZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07059650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingTargeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Early phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07093411
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad Hospital; 3 listed hospitals as study sitesBeijing, Hefei, Xi'an, Xuzhou
- RecruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07154264
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- RecruitingPA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07188610
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingThe Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2024-03
- Posted
- Registry
- NCT06307600
Age 3 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingTargeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06395870
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteHefei, Tianjin
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingSelinexor in Combination With MTX+Ritu to Treat R/R CNSL
- Phase
- Phase 1/Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT05698147
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Hefei, Shanghai, Zhengzhou
- RecruitingA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06136559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase
- Phase 3
- Started
- 2022-07
- Posted
- Registry
- NCT05254743
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
- RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Phase
- Phase 1/Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05294731
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Hefei
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital, Anhui University of Chinese Medicine安徽中医药大学神经病学研究所附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Anhui Chest Hospital安徽省胸科医院 | none | none | none | none | 16 | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Anhui Chest Hospital | none | none | none | none | 11 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Anhui Provincial Cancer Hospital安徽省肿瘤医院 | none | 0 | none | 0 | 1 | 0 | 0 | none | none | none | none | 0 | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | |
| Anhui Provincial Children's Hospital安徽省儿童医院 | none | none | none | none | none | none | none | none | 1 | 1 | none | none | none | 8 | none | none | 1 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 2 | none | 3 | none | none | none | none | none | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 0 | none | none | none | none | |
| First Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院 | 3 | 23 | 101 | 84 | 82 | 25 | 67 | 32 | none | 0 | none | 13 | 0 | 1 | 1 | 10 | none | 1 | none | 9 | none | none | none | 2 | 1 | none | none | 4 | none | 1 | none | 22 | 8 | none | 7 | 2 | none | 5 | none | none | none | none | none | 0 | none | none | 11 | none | 0 | none | 3 | 2 | 0 | 1 | 2 | none | 0 | 1 | none | none | none | |
| First Affiliated Hospital of Anhui University of Chinese Medicine安徽中医药大学第一附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 52 | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院) | 2 | 176 open | 914 open | 22 | 682 open | 20 | 52 | 44 | none | none | none | 3 | 4 | 4 | none | 22 open | 12 open | 21 open | none | 133 open | none | 2 | none | 1 | 0 | 0 | none | 1 | 5 | 6 | none | 18 | 6 | none | 0 | none | none | 2 | 1 | 1 | none | 2 | none | none | 0 | 1 | 1 | none | none | none | 0 | 0 | 0 | 1 | none | none | none | none | none | none | none | |
| Fourth Affiliated Hospital of Anhui Medical University安徽医科大学第四附属医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hefei Binhu Hospital合肥市第一人民医院滨湖院区 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hefei BOE Hospital合肥京东方医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hefei Maternal and Child Health Hospital合肥市妇幼保健院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Internet Hospital平安(合肥)互联网医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Police Forces Anhui Provincial Corps Hospital武警安徽省总队医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Anhui Medical University安徽医科大学第二附属医院 | none | 1 | 27 | 21 | 28 | 3 | 381 open | 17 | none | 1 | none | 6 | 1 | 2 | 1 | 7 | 4 | none | 1 | 16 | none | 4 | none | 1 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | 0 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | |
| South District Binhu Hospital合肥市第一人民医院南区 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Anhui Medical University合肥市第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Hefei.
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 23
- Hepatocellular carcinoma 101
- Stomach cancer 84
- Lung cancer 82
- Pancreatic cancer 25
- Breast cancer 67
- Glioma 32
- Retinoblastoma 0
- Osteosarcoma 13
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Ewing sarcoma 1
- Multiple myeloma 10
- Aplastic anaemia 1
- Lymphoma 9
- Thrombotic thrombocytopenic purpura 2
- Fanconi anaemia 1
- Myasthenia gravis 4
- Wilson disease 1
- Coronary heart disease 22
- Congenital heart disease 8
- Anti-NMDA receptor encephalitis 7
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 5
- Duchenne muscular dystrophy 0
- IgA nephropathy 11
- Niemann–Pick disease type C 0
- Primary biliary cholangitis 3
- Primary sclerosing cholangitis 2
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 1
- Inherited epidermolysis bullosa 2
- Familial adenomatous polyposis 0
- Leber hereditary optic neuropathy 1
- Nasopharyngeal carcinoma 2
- Oesophageal squamous cell carcinoma 176 open
- Hepatocellular carcinoma 914 open
- Stomach cancer 22
- Lung cancer 682 open
- Pancreatic cancer 20
- Breast cancer 52
- Glioma 44
- Osteosarcoma 3
- Gastrointestinal stromal tumour 4
- Neuroblastoma 4
- Multiple myeloma 22 open
- B-cell acute lymphoblastic leukaemia 12 open
- Aplastic anaemia 21 open
- Lymphoma 133 open
- Haemophilia A 2
- Thrombotic thrombocytopenic purpura 1
- Fanconi anaemia 0
- Neuromyelitis optica spectrum disorder 0
- Myasthenia gravis 1
- Moyamoya disease 5
- Wilson disease 6
- Coronary heart disease 18
- Congenital heart disease 6
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 2
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 1
- Fabry disease 2
- Behçet disease 0
- Alport syndrome 1
- IgA nephropathy 1
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 1
- Oesophageal squamous cell carcinoma 1
- Hepatocellular carcinoma 27
- Stomach cancer 21
- Lung cancer 28
- Pancreatic cancer 3
- Breast cancer 381 open
- Glioma 17
- Retinoblastoma 1
- Osteosarcoma 6
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Ewing sarcoma 1
- Multiple myeloma 7
- B-cell acute lymphoblastic leukaemia 4
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 16
- Haemophilia A 4
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 2
- Idiopathic pulmonary fibrosis 4
- IgA nephropathy 0
- Primary biliary cholangitis 1
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Hefei on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.